Loading

Please wait...

Exjade

Generic Name: deferasirox (de FER a sir ox)
Brand Names: Exjade
Exjade is used to treat iron overload caused by blood transfusions. Learn about side effects, interactions and indications.
  • Prescription Settings
  • X
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.
  • Learn more

Exjade Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Exjade (deferasirox) binds to iron and removes it from the bloodstream. Exjade is used to treat iron overload caused by blood transfusions in adults and children at least 2 years old. Exjade is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion-dependent thalassemia) in adults and children who are at least 10 years old. You should not use Exjade if you have severe kidney or liver disease, advanced cancer, a blood cell or bone marrow disorder, or low levels of platelets in your blood. Learn more

Pickup / Home Delivery

USARx offers multiple ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price
    Local Pharmacy Pickup

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply
    Mail Order Home Delivery

    The easiest way to receive your medications.

Exjade Side Effects

Note: This document contains side effect information about deferasirox. Some of the dosage forms listed on this page may not apply to the brand name Exjade.

In Summary

Common side effects of Exjade include: abdominal pain, cough, diarrhea, fever, headache, increased serum creatinine, influenza, nasopharyngitis, nausea, proteinuria, vomiting, and pharyngolaryngeal pain. Other side effects include: otic infection, respiratory tract infection, arthralgia, back pain, bronchitis, fatigue, increased serum alanine aminotransferase, pharyngitis, rhinitis, skin rash, tonsillitis, and upper abdominal pain. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to deferasirox: oral granule, oral tablet, oral tablet for suspension

Warning

Oral route (Tablet; Tablet for Suspension; Granule)

Renal Failure:Deferasirox can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders.Evaluate baseline renal function prior to starting or increasing deferasirox dosing in all patients. Deferasirox is contraindicated in adult and pediatric patients with estimated GFR less than 40 mL/min/1.73 m(2). Measure serum creatinine in duplicate prior to initiation of therapy. Monitor renal function at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, then at least monthly. Reduce the starting dose in patients with pre-existing renal disease. During therapy, increase the frequency of monitoring and modify the dose for patients with an increased risk of renal impairment, including use of concomitant nephrotoxic drugs, and pediatric patients with volume depletion or overchelation.Hepatic Failure:Deferasirox can cause hepatic injury including hepatic failure and death Measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly thereafter.Avoid use of deferasirox in patients with severe (Child-Pugh C) hepatic impairment and reduce the dose in patients with moderate (Child Pugh B) hepatic impairment.Gastrointestinal Hemorrhage:Deferasirox can cause gastrointestinal (GI) hemorrhages, which may be fatal, especially in elderly patients who have advanced hematologic malignancies and/or low platelet counts.Monitor patients and discontinue deferasirox for suspected GI ulceration or hemorrhage..

Along with its needed effects, deferasirox (the active ingredient contained in Exjade) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking deferasirox:

More common

  • Diarrhea
  • dizziness
  • earache or pain in the ear
  • nausea
  • stomach pain
  • voice changes
  • vomiting

Rare

  • Blindness
  • blurred vision
  • change in hearing
  • change in vision
  • pain or discomfort in the eye

Incidence not known

  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • dark urine
  • decrease in the amount of urine
  • general feeling of tiredness or weakness
  • hives, welts, skin rash
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
  • light-colored stools
  • lower back or side pain
  • pale skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • redness, soreness, itching of the skin
  • sores, blisters
  • stomach pain, continuing
  • unusual bleeding or bruising
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • vomiting of blood or material that looks like coffee grounds
  • yellow eyes or skin

For Healthcare Professionals

Applies to deferasirox: oral granule for reconstitution, oral tablet, oral tablet dispersible

General

The most common adverse events were abdominal pain, nausea, vomiting, diarrhea, skin rashes, and increases in serum creatinine. Gastrointestinal symptoms, increases in serum creatinine, and skin rash were dose related.

Gastrointestinal

Very common (10% or more): Diarrhea (up to 47%), abdominal pain (28%), nausea (26%), vomiting (21%)

Common (1% to 10%): Abdominal pain upper, constipation, abdominal distension, dyspepsia

Uncommon (0.1% to 1%): Gastritis, gastrointestinal hemorrhage, gastric ulcer (including multiple ulcers), duodenal ulcer, esophagitis

Frequency not reported: Pancreatitis associated with gallstones (with and without underlying biliary conditions)

Postmarketing reports: Gastrointestinal perforation

Renal

Very common (10% or more): Creatinine increased (38%)

Common (1% to 10%): Abnormal serum creatinine, abnormal creatinine clearance values

Uncommon (0.1% to 1%): Renal tubulopathy (Fanconi's Syndrome)

Postmarketing reports: Renal tubular necrosis, acute renal failure, tubulointerstitial nephritis, acute kidney injury, decreased eGFR, renal tubular disorder

Dermatologic

Very common (10% or more): Rash (13%)

Common (1% to 10%): Urticaria, pruritus

Uncommon (0.1% to 1%): Henoch Schonlein purpura, pigmentation disorder, erythema multiforme, drug reaction with eosinophilia and systemic symptoms (DRESS)

Postmarketing reports: Stevens-Johnson syndrome, leukocytoclastic vasculitis, alopecia, toxic epidermal necrolysis

Genitourinary

Very common (10% or more): Intermittent proteinuria (18.6%)

Common (1% to 10%): Proteinuria

Uncommon (0.1% to 1%): Glycosuria

Postmarketing reports: Hematuria

Respiratory

Very common (10% or more): Cough (13.9%), nasopharyngitis (13.2%), influenza, (10.8%), pharyngolaryngeal pain (10.5%)

Common (1% to 10%): Respiratory tract infection, bronchitis, pharyngitis, acute tonsillitis, rhinitis

Other

Very common (10% or more): Pyrexia (18.9%)

Common (1% to 10%): Death, fatigue, ear infection

Uncommon (0.1% to 1%): Drug fever, hearing loss

Nervous system

Very common (10% or more): Headache (15.9%)

Uncommon (0.1% to 1%): Hyperactivity, dizziness

Hepatic

Common (1% to 10%): Elevations in SGPT/ALT, gallstones, drug induced hepatitis, abnormal liver function tests, transaminases increased

Uncommon (0.1% to 1%): Cholelithiasis, hepatitis

Postmarketing reports: Hepatic failure

Musculoskeletal

Common (1% to 10%): Arthralgia, back pain

Ocular

Uncommon (0.1% to 1%): Cataract, maculopathy, early cataract, optic neuritis

Metabolic

Uncommon (0.1% to 1%): Edema

Postmarketing reports: Metabolic acidosis, hypokalemia

Psychiatric

Uncommon (0.1% to 1%): Insomnia, sleep disorder, anxiety

Hematologic

Postmarketing reports: Worsening anemia, cytopenias including neutropenia and thrombocytopenia, pancytopenia

Hypersensitivity

Postmarketing reports: Hypersensitivity reactions (including anaphylaxis and angioedema)

Immunologic

Frequency not reported: Atypical tuberculosis

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Exjade (www.drugs.com/exjade.html).